Arbutus Biopharma (ABUS)
Arbutus Biopharma on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq.
24.6M
Short interest
settlement 2026-10-15
4.3
Days to cover
+0.8 days vs prior
54.4%
Short share of volume
2026-11-02
15,982
Fails to deliver
settlement 2026-10-14
Thu 12 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ABUS is 24,566,591 shares, up 6,081,681 shares over the last month. Over the last 48 readings it ranged from 5,821,160 shares (29 November 2024) to 34,053,358 shares (30 September 2026). At the reported average volume of 5.7M shares a day that is 4.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/abus" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 24,566,591 | -27.9% | 5,655,826 | 4.34 |
| 2026-09-30 | 34,053,358 | +84.2% | 9,652,199 | 3.53 |
| 2026-09-15 | 18,484,910 | -2.3% | 3,691,181 | 5.01 |
| 2026-08-31 | 18,916,119 | +2.5% | 6,139,181 | 3.08 |
| 2026-08-14 | 18,456,085 | -8.8% | 1,222,134 | 15.10 |
| 2026-07-31 | 20,236,241 | +3.0% | 1,478,060 | 13.69 |
| 2026-07-15 | 19,653,287 | +14.8% | 2,655,278 | 7.40 |
| 2026-06-30 | 17,111,453 | -2.4% | 3,499,322 | 4.89 |
| 2026-06-15 | 17,522,670 | +3.2% | 1,255,250 | 13.96 |
| 2026-05-29 | 16,982,764 | +3.3% | 1,849,722 | 9.18 |
| 2026-05-15 | 16,438,082 | -7.4% | 962,486 | 17.08 |
| 2026-04-30 | 17,743,389 | -0.3% | 2,476,388 | 7.17 |
| 2026-04-15 | 17,803,913 | +10.1% | 1,556,792 | 11.44 |
| 2026-03-31 | 16,174,093 | -1.4% | 2,297,163 | 7.04 |
| 2026-03-13 | 16,405,599 | +11.2% | 3,927,055 | 4.18 |
| 2026-02-27 | 14,756,509 | -1.6% | 1,550,244 | 9.52 |
| 2026-02-13 | 14,998,521 | +10.6% | 2,334,202 | 6.43 |
| 2026-01-30 | 13,558,940 | +3.8% | 1,815,351 | 7.47 |
| 2026-01-15 | 13,067,041 | +4.2% | 1,073,545 | 12.17 |
| 2025-12-31 | 12,535,638 | +16.7% | 1,451,951 | 8.63 |
| 2025-12-15 | 10,740,954 | -4.2% | 1,156,866 | 9.28 |
| 2025-11-28 | 11,206,745 | +6.1% | 1,135,178 | 9.87 |
| 2025-11-14 | 10,563,698 | +6.5% | 983,752 | 10.74 |
| 2025-10-31 | 9,916,540 | +0.5% | 958,117 | 10.35 |
| 2025-10-15 | 9,863,869 | -2.7% | 937,420 | 10.52 |
| 2025-09-30 | 10,136,672 | -9.2% | 1,060,185 | 9.56 |
| 2025-09-15 | 11,160,517 | +5.8% | 2,155,961 | 5.18 |
| 2025-08-29 | 10,546,749 | -15.7% | 948,298 | 11.12 |
| 2025-08-15 | 12,514,972 | -3.6% | 686,975 | 18.22 |
| 2025-07-31 | 12,983,847 | -4.8% | 637,213 | 20.38 |
| 2025-07-15 | 13,636,945 | -1.0% | 731,232 | 18.65 |
| 2025-06-30 | 13,770,774 | +7.2% | 1,096,756 | 12.56 |
| 2025-06-13 | 12,841,350 | +0.7% | 516,105 | 24.88 |
| 2025-05-30 | 12,751,934 | +10.8% | 798,705 | 15.97 |
| 2025-05-15 | 11,504,318 | +2.8% | 860,489 | 13.37 |
| 2025-04-30 | 11,190,235 | +1.2% | 790,883 | 14.15 |
| 2025-04-15 | 11,054,234 | +12.3% | 1,456,178 | 7.59 |
| 2025-03-31 | 9,847,908 | +2.9% | 960,820 | 10.25 |
| 2025-03-14 | 9,574,515 | +13.8% | 1,017,579 | 9.41 |
| 2025-02-28 | 8,411,716 | +16.6% | 1,189,667 | 7.07 |
| 2025-02-14 | 7,212,196 | +7.3% | 624,275 | 11.55 |
| 2025-01-31 | 6,722,546 | +1.3% | 577,474 | 11.64 |
| 2025-01-15 | 6,637,358 | +11.6% | 833,798 | 7.96 |
| 2024-12-31 | 5,948,529 | -0.4% | 992,848 | 5.99 |
| 2024-12-13 | 5,972,229 | +2.6% | 694,170 | 8.60 |
| 2024-11-29 | 5,821,160 | -3.9% | 878,226 | 6.63 |
| 2024-11-15 | 6,055,854 | -7.5% | 969,178 | 6.25 |
| 2024-10-31 | 6,543,356 | -16.0% | 895,859 | 7.30 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ABUS volume is 54.4%, down 21.2 points over the last five sessions. Over the last 30 readings it ranged from 13.9% (22 September 2026) to 77.7% (24 September 2026). The latest reading is 5.2 points below the 30-session average of 59.7%, on 1.1M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 609K | 1.1M | 54.4% | 215 |
| 2026-10-30 | 511K | 905K | 56.5% | 902 |
| 2026-10-29 | 196K | 322K | 60.8% | 87 |
| 2026-10-28 | 182K | 369K | 49.2% | 0 |
| 2026-10-27 | 373K | 633K | 58.9% | 0 |
| 2026-10-26 | 316K | 418K | 75.7% | 100 |
| 2026-10-23 | 624K | 938K | 66.5% | 197 |
| 2026-10-22 | 375K | 952K | 39.5% | 1,423 |
| 2026-10-21 | 585K | 1.5M | 38.7% | 6,751 |
| 2026-10-20 | 358K | 697K | 51.4% | 0 |
| 2026-10-19 | 426K | 623K | 68.3% | 20 |
| 2026-10-16 | 784K | 1.0M | 74.8% | 12 |
| 2026-10-15 | 560K | 787K | 71.2% | 24 |
| 2026-10-14 | 575K | 789K | 72.9% | 15 |
| 2026-10-13 | 791K | 1.1M | 74.1% | 6 |
| 2026-10-12 | 561K | 930K | 60.3% | 501 |
| 2026-10-09 | 468K | 1.1M | 42.0% | 3,993 |
| 2026-10-08 | 925K | 1.6M | 59.0% | 6,330 |
| 2026-10-07 | 792K | 1.2M | 64.0% | 1,310 |
| 2026-10-06 | 1.2M | 1.7M | 66.6% | 47 |
| 2026-10-05 | 649K | 1.3M | 50.9% | 130 |
| 2026-10-02 | 1.4M | 2.8M | 49.2% | 900 |
| 2026-10-01 | 2.0M | 3.8M | 52.1% | 0 |
| 2026-09-30 | 3.7M | 5.1M | 71.7% | 3,254 |
| 2026-09-29 | 2.8M | 4.4M | 64.0% | 0 |
| 2026-09-28 | 2.9M | 4.6M | 64.2% | 5 |
| 2026-09-25 | 3.1M | 4.1M | 75.8% | 2,937 |
| 2026-09-24 | 1.6M | 2.1M | 77.7% | 138 |
| 2026-09-23 | 2.0M | 3.1M | 65.9% | 205 |
| 2026-09-22 | 368K | 2.7M | 13.9% | 1,500 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in ABUS is 15,982 shares, up 15,980 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (9 October 2026) to 2,641,844 shares (2 October 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 15,982 | $4.11 | $66K |
| 2026-10-09 | 2 | $4.18 | $8 |
| 2026-10-07 | 1,000 | $4.48 | $4K |
| 2026-10-05 | 1,190,578 | $4.45 | $5.3M |
| 2026-10-02 | 2,641,844 | $4.56 | $12.0M |
| 2026-09-24 | 9,000 | $4.85 | $44K |
| 2026-09-23 | 9,000 | $5.01 | $45K |
| 2026-09-21 | 1,540 | $5.01 | $8K |
| 2026-09-18 | 5,119 | $5.07 | $26K |
| 2026-09-15 | 4,861 | $5.13 | $25K |
| 2026-09-14 | 903 | $5.12 | $5K |
| 2026-09-11 | 4 | $5.12 | $20 |
| 2026-09-10 | 22,417 | $5.17 | $116K |
| 2026-09-09 | 20,763 | $5.18 | $108K |
| 2026-09-04 | 87,805 | $5.12 | $450K |
| 2026-08-31 | 44 | $5.07 | $223 |
| 2026-08-28 | 4,141 | $5.17 | $21K |
| 2026-08-25 | 8,402 | $5.20 | $44K |
| 2026-08-24 | 14,176 | $5.21 | $74K |
| 2026-08-12 | 25,611 | $4.67 | $120K |
| 2026-07-27 | 85 | $4.38 | $372 |
| 2026-07-17 | 105 | $4.74 | $498 |
| 2026-07-16 | 1,525 | $4.56 | $7K |
| 2026-07-01 | 1,396 | $4.80 | $7K |
| 2026-06-30 | 149,841 | $4.68 | $701K |
| 2026-06-29 | 167,844 | $4.58 | $769K |
| 2026-06-25 | 1,073 | $4.46 | $5K |
| 2026-06-23 | 120 | $4.52 | $542 |
| 2026-06-17 | 162 | $4.39 | $711 |
| 2026-06-12 | 68 | $4.29 | $292 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for ABUS in the last 90 days. The most recent filings are listed below. Latest filing: Beardsley Robert A (Director) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Beardsley Robert A | Director | Returned to company | 18K | $5.00 | $90K | 14K |
| 2026-10-01 | Nguyen Tuan | Chief Financial Officer | Returned to company | 48K | $5.00 | $240K | 112K |
| 2026-10-01 | Sawhney Roger | Director | Returned to company | 17K | $5.00 | $86K | 14K |
| 2026-10-01 | Androski Lindsay | President and CEO | Returned to company | 25K | $5.00 | $123K | 48K |
| 2026-10-01 | Roivant Sciences Ltd. | Director, 10% owner | Returned to company | 9.0M | $5.00 | $44.8M | 29.9M |
| 2026-09-18 | Beardsley Robert A | Director | Tax withholding | 99K | $5.07 | $502K | 32K |
| 2026-09-18 | Beardsley Robert A | Director | Exercise or conversion | 79K | $4.24 | $334K | 131K |
| 2026-09-18 | Beardsley Robert A | Director | Exercise or conversion | 53K | $3.20 | $168K | 53K |
| 2026-09-18 | Sawhney Roger | Director | Tax withholding | 101K | $5.07 | $510K | 31K |
| 2026-09-18 | Sawhney Roger | Director | Exercise or conversion | 79K | $4.24 | $334K | 131K |
| 2026-09-18 | Sawhney Roger | Director | Exercise or conversion | 53K | $3.34 | $175K | 53K |
| 2026-09-18 | Nguyen Tuan | Chief Financial Officer | Tax withholding | 207K | $5.07 | $1.0M | 160K |
| 2026-09-18 | Nguyen Tuan | Chief Financial Officer | Exercise or conversion | 27K | $4.39 | $121K | 367K |
| 2026-09-18 | Nguyen Tuan | Chief Financial Officer | Exercise or conversion | 266K | $3.49 | $927K | 339K |
| 2026-09-18 | Androski Lindsay | President and CEO | Tax withholding | 83K | $5.07 | $418K | 72K |
| 2026-09-18 | Androski Lindsay | President and CEO | Exercise or conversion | 10K | $4.39 | $46K | 155K |
| 2026-09-18 | Androski Lindsay | President and CEO | Exercise or conversion | 116K | $3.20 | $373K | 144K |
| 2026-02-02 | Nguyen Tuan | Chief Financial Officer | Grant | 74K | $0.00 | $0 | 74K |
| 2026-02-02 | Androski Lindsay | President and CEO | Grant | 28K | $0.00 | $0 | 28K |
| 2025-02-14 | Sims Karen | Chief Medical Officer | Grant | 49K | $0.00 | $0 | 155K |
| 2025-02-14 | HASTINGS DAVID C | Chief Financial Officer | Grant | 90K | $0.00 | $0 | 250K |
| 2025-02-14 | McElhaugh Michael J. | Interim President & CEO | Grant | 177K | $0.00 | $0 | 1.7M |
| 2025-02-14 | Naftzger J. Christopher | General Counsel and CCO | Grant | 54K | $0.00 | $0 | 141K |
| 2025-02-04 | Naftzger J. Christopher | General Counsel and CCO | Sell | 11K | $3.28 | $37K | 86K |
| 2025-02-04 | McElhaugh Michael J. | Interim President & CEO | Sell | 24K | $3.28 | $78K | 1.5M |
| 2025-02-04 | Sims Karen | Chief Medical Officer | Sell | 19K | $3.28 | $63K | 106K |
| 2025-02-04 | HASTINGS DAVID C | Chief Financial Officer | Sell | 22K | $3.28 | $73K | 160K |
| 2024-08-14 | MANCHESTER KEITH S | Director | Exercise or conversion | 55K | $0.56 | $31K | 55K |
| 2024-08-14 | MANCHESTER KEITH S | Director | Sell | 9K | $3.69 | $33K | 46K |
| 2024-02-02 | McElhaugh Michael J. | Interim President & CEO | Sell | 10K | $2.31 | $23K | 1.5M |
| 2024-02-02 | Sofia Michael J. | Chief Scientific Officer | Sell | 10K | $2.31 | $23K | 1.5M |
| 2024-02-02 | HASTINGS DAVID C | Chief Financial Officer | Sell | 10K | $2.31 | $22K | 182K |
| 2024-02-02 | Sims Karen | Chief Medical Officer | Sell | 4K | $2.31 | $10K | 126K |
| 2024-02-01 | McElhaugh Michael J. | Interim President & CEO | Grant | 124K | $0.00 | $0 | 1.5M |
| 2024-02-01 | Sofia Michael J. | Chief Scientific Officer | Grant | 110K | $0.00 | $0 | 1.5M |
| 2024-02-01 | HASTINGS DAVID C | Chief Financial Officer | Grant | 113K | $0.00 | $0 | 192K |
| 2024-02-01 | Sims Karen | Chief Medical Officer | Grant | 101K | $0.00 | $0 | 130K |
| 2024-02-01 | Naftzger J. Christopher | General Counsel and CCO | Grant | 95K | $0.00 | $0 | 95K |
| 2023-02-01 | Howard Elizabeth | EVP, GC, Compliance | Grant | 70K | $0.00 | $0 | 86K |
| 2023-02-01 | Collier William H. | President and CEO | Grant | 217K | $0.00 | $0 | 217K |
| 2023-02-01 | HASTINGS DAVID C | Chief Financial Officer | Grant | 79K | $0.00 | $0 | 79K |
| 2023-02-01 | Sofia Michael J. | Chief Scientific Officer | Grant | 82K | $0.00 | $0 | 1.4M |
| 2023-02-01 | McElhaugh Michael J. | Chief Business Officer | Grant | 84K | $0.00 | $0 | 1.4M |
| 2021-12-01 | Sofia Michael J. | Chief Scientific Officer | Sell | 200K | $5.09 | $1.0M | 1.3M |
| 2021-10-18 | Roivant Sciences Ltd. | TenPercentOwner | Conversion | 22.8M | price not stated in the filing | not stated | 38.8M |
| 2021-02-09 | McElhaugh Michael J. | Chief Business Officer | Sell | 20K | $5.00 | $100K | 1.3M |
| 2020-12-14 | McElhaugh Michael J. | Chief Business Officer | Sell | 30K | $5.00 | $150K | 1.3M |
| 2020-12-14 | McElhaugh Michael J. | Chief Business Officer | Sell | 10K | $5.00 | $50K | 1.3M |
| 2020-07-23 | McElhaugh Michael J. | Chief Business Officer | Sell | 20K | $5.01 | $100K | 1.4M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of ABUS in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Roivant Sciences Ltd. at 19.5% of the class (29,880,079 shares), filed 2026-10-05 for an event on 2026-10-01.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 2 | BlackRock, Inc.parent holding company | 14.3M | 7.2% | 2026-09-30 |
| 2026-10-07 | 13G/Ano. 4 | Morgan Stanleyparent holding company, corporation | 18.7M | 12.2% | 2026-09-30 |
| 2026-10-07 | 13G/Ano. 4 | Morgan Stanley Investment Management Inc.investment adviser, corporation | 17.4M | 11.3% | 2026-09-30 |
| 2026-10-05 | 13D/Ano. 14 | Roivant Sciences Ltd.corporation | 29.9M | 19.5% | 2026-10-01 |
| 2026-09-04 | 13G | David Salanicparent holding company, individual | 15.8M | 8.0% | 2026-09-04 |
| 2026-09-04 | 13G | Joseph Kaplanparent holding company, individual | 15.8M | 8.0% | 2026-09-04 |
| 2026-09-04 | 13G | Whitefort Capital Management GP, LLCother entity | 15.8M | 8.0% | 2026-09-04 |
| 2026-09-04 | 13G | Whitefort Capital Master Fund, LPpartnership | 15.8M | 8.0% | 2026-09-04 |
| 2026-09-04 | 13G | Whitefort Capital GP, LLCother entity | 15.8M | 8.0% | 2026-09-04 |
| 2026-09-04 | 13G | Whitefort Capital Management, LPinvestment adviser, partnership | 15.8M | 8.0% | 2026-09-04 |
| 2026-05-15 | 13G/Ano. 2 | Sina Toussiindividual, parent holding company | 18.6M | 9.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Two Seas Capital GP LLCother entity, parent holding company | 18.6M | 9.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Two Seas Capital LPinvestment adviser, partnership | 18.6M | 9.4% | 2026-03-31 |
13F holders
Tracked managers holding ABUS at their latest 13F. JSON4 of the 30 tracked managers held ABUS at their latest 13F, $4.3M in total at quarter-end prices. Citadel Advisors is the largest at $1.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 405K | $1.9M | 0.00% | -272K |
| D. E. Shaw & Co. | 2026-06-30 | 382K | $1.8M | 0.00% | +239K |
| Two Sigma Investments | 2026-06-30 | 85K | $408K | 0.00% | new |
| AQR Capital Management | 2026-06-30 | 32K | $152K | 0.00% | +8K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Arbutus Biopharma in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Arbutus Biopharma (ABUS), SEC CIK 1447028, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1447028Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
- SYRESpyre Therapeutics
- SYYSysco
- TAT&T
- TAPMolson Coors
- TCOMTrip.com Group
- TDToronto-Dominion Bank
- TDGTransDigm Group
- TDYTeledyne Technologies
Datasets
Frequently Asked Questions
How much of ABUS is sold short?
What is ABUS's daily short volume?
Does ABUS have fails to deliver?
Are ABUS insiders buying or selling?
Who owns 5% or more of ABUS?
Which tracked 13F managers own ABUS?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.